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Endocannabinoids and cannabinoid 1 (CB1) receptors have been
implicated in cardiac dysfunction, inﬂammation, and cell death as-
sociated with various forms of shock, heart failure, and atheroscle-
rosis, in addition to their recognized role in the development of
various cardiovascular risk factors in obesity/metabolic syndrome
and diabetes. In this study, we explored the role of CB1 receptors in
myocardial dysfunction, inﬂammation, oxidative/nitrative stress,
cell death, and interrelated signaling pathways, using a mouse
model of type 1 diabetic cardiomyopathy. Diabetic cardiomyop-
athy was characterized by increased myocardial endocannabinoid
anandamide levels, oxidative/nitrative stress, activation of p38/Jun
NH2-terminal kinase (JNK) mitogen-activated protein kinases
(MAPKs), enhanced inﬂammation (tumor necrosis factor-a, inter-
leukin-1b, cyclooxygenase 2, intracellular adhesion molecule 1,
and vascular cell adhesion molecule 1), increased expression of
CB1, advanced glycation end product (AGE) and angiotensin II
type 1 receptors (receptor for advanced glycation end product
[RAGE], angiotensin II receptor type 1 [AT1R]), p47(phox) NADPH
oxidase subunit, b-myosin heavy chain isozyme switch, accumula-
tion of AGE, ﬁbrosis, and decreased expression of sarcoplasmic/
endoplasmic reticulum Ca2+-ATPase (SERCA2a). Pharmacological
inhibition or genetic deletion of CB1 receptors attenuated the
diabetes-induced cardiac dysfunction and the above-mentioned
pathological alterations. Activation of CB1 receptors by endo-
cannabinoids may play an important role in the pathogenesis of
diabetic cardiomyopathy by facilitating MAPK activation, AT1R
expression/signaling, AGE accumulation, oxidative/nitrative stress,
inﬂammation, and ﬁbrosis. Conversely, CB1 receptor inhibition
may be beneﬁcial in the treatment of diabetic cardiovascular com-
plications. Diabetes 61:716–727, 2012
In diabetic patients, cardiovascular complications re-present the principal cause of morbidity and mor-tality. Myocardial left ventricular (LV) dysfunction(both diastolic and later systolic) independent of
atherosclerosis and coronary artery disease has been well
documented in both humans and animals (1,2). The mecha-
nisms of diabetic cardiomyopathy are multifaceted, involving
increased oxidative/nitrosative stress (3–6,), accumulation
of advanced glycation end products (AGEs) (7–9), enhanced
receptor for advanced glycation end product (RAGE)
and angiotensin II receptor type 1 (AT1R) signaling (3,7–13),
activation of various proinﬂammatory and cell death signal-
ing pathways [e.g., poly(ADP-ribose) polymerase (PARP)],
mitogen-activated protein kinases (MAPKs) (10,14–16),
coupled with consequent changes in the composition of ex-
tracellular matrix with enhanced cardiac ﬁbrosis (13,16),
myosin heavy chain (MHC) isoform switch (17), and de-
creased activity of sarcoplasmic/endoplasmic reticulum
Ca2+-ATPase (SERCA2a) (18–20), just to mention a few.
Recent preclinical and clinical studies have importantly
implicated endocannabinoids (novel lipid mediators) and
cannabinoid 1 (CB1) receptors (CB1Rs) in the regulation of
food intake, energy balance, and metabolism (21–23).
CB1R inhibition with rimonabant (SR141716/SR1) demon-
strated multiple beneﬁcial effects on metabolic and in-
ﬂammatory markers both in obese and/or type 2 diabetic
patients, as well as in various preclinical disease models
(21,23). CB1Rs are predominantly expressed in the central
nervous system (21), but are also present in cardiovascu-
lar and virtually all other peripheral tissues, albeit at much
lower levels (24,25). In the cardiovascular system, CB1
activation by endocannabinoids or synthetic ligands leads
to complex cardiovascular depressive effects, impli-
cated in the cardiovascular collapse associated with
various forms of shock (21) and heart failure (26–28).
CB1R activation in coronary artery endothelial cells (29),
cardiomyocytes (26,27), and inﬂammatory cells (28,30) me-
diates MAPK activation, reactive oxygen species (ROS)
generation, and inﬂammatory response promoting athero-
sclerosis (31) and cardiac dysfunction (27,28). Furthermore,
elevated endocannabinoid plasma levels have recently been
associated with coronary circulatory dysfunction in human
obesity (32), and CB1R blockade or its genetic deletion at-
tenuated proteinuria and/or vascular inﬂammation and cell
death in experimental models of type 1 diabetic nephropa-
thy (33) and/or retinopathy (34). Beneﬁcial effect of CB1
blockade has also been reported in rodent models of type 1
diabetic neuropathy and in various high glucose–induced
in vitro experimental paradigms (rev. in 35).
In this study, we investigated the potential role of the
endocannabinoids and CB1R in the pathogenesis of type 1
diabetic cardiomyopathy using selective CB1R inhibitors or
CB1 knockout mice. Our results demonstrate that pharma-
cological inhibition or genetic deletion of CB1 attenuates
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cardiac dysfunction, oxidative stress, inﬂammation, and
ﬁbrosis in diabetic mice.
RESEARCH DESIGN AND METHODS
Animals and treatment. Animal protocols used in this study adhered to the
National Institutes of Health (NIH) guidelines and were approved by the In-
stitutional Animal Care and Use Committee of the National Institute on Alcohol
Abuse and Alcoholism (NIAAA). Diabetes was induced in 8- to 12-week-old C57/
BL6J(WT) mice (male, The Jackson Laboratories, Bar Harbor, ME) or CB1
+/+
CB1
2/2 mice (on C57/BL6J background; Intramural Research Program of NIH/
NIAAA, Rockville, MD) weighing 23–25 g by intraperitoneal administration of
streptozotocin (STZ) (Sigma, St. Louis, MO) at the dose of 50 mg/kg dissolved
in 100 mmol/L citrate buffer, pH 4.5, for 5 consecutive days as described (16).
After 5 days, the blood glucose levels were measured using an Ascensia Counter
Glucometer (Bayer HealthCare, Tarrytown, NY) by mandibular puncture blood
sampling. Only mice that had blood glucose values .250 mg/dL were used for
the study. Control animals were administered the same volume of citrate buffer,
and all mice had access to food and water ad libitum. Diabetes was allowed
to develop further for 1 additional week before animals were treated for
11 weeks with the selective CB1R antagonists (SR141716A/rimonabant and
AM281; 10 mg/kg i.p. daily; National Institute on Drug Abuse Drug Supply
Program, Research Triangle Park, NC) or corresponding vehicle. After 12
weeks, animals were subjected to hemodynamic measurements (described
below), and hearts were excised and snap-frozen in liquid nitrogen for bio-
chemical determinations or ﬁxed in formalin for histological evaluations. The
treatment protocols are detailed in Supplementary Figs. 1 and 2. In a separate
set of experiments, 8-week diabetic mice were treated with SR141716A/
rimonabant or vehicle for 4 weeks before hemodynamic measurements
(Supplementary Fig. 6).
Hemodynamic measurements. LV performance was measured and evaluated
in mice anesthetized with 2% isoﬂurane using a 1F microtip pressure-volume
catheter (PVR 1045; Millar Instruments, Houston, TX) coupled with an ARIA
pressure-volume conductance system (Millar Instruments) and a Powerlab/4SP
A/D converter (AD Instruments, Mountain View, CA), as previously described
(26,36).
Determination ofmyocardial endocannabinoids content.Hearts were excised
and immediately snap-frozen in liquid nitrogen, and samples were stored in280°C
until analysis. Endocannabinoids anandamide (N-arachidonoylethanolamide;
AEA) and N-arachidonyl-glycerol (2-AG) in various heart tissues were de-
termined with liquid chromatography–mass spectrophotometry as previously
described (26).
Pancreas insulin content. Pancreatic insulin content was determined using
the kit obtained from ALPCO Diagnostics (Salem, NH), by following the ex-
traction procedure described previously (16).
Determination of HbA1c. HbA1c levels in EDTA whole blood was determined
using the commercially available reagents procured from Stanbio Laboratory
(Boerne, TX) (16).
Reverse transcription and real-time PCR. LV myocardial tissues were
homogenized and total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruction. The RNA was
treated with RNase-free DNase (Ambion, TX) to remove genomic DNA con-
tamination. Total RNA was then reverse-transcribed to cDNA using the Super-
Script II (Invitrogen), and the target genes were ampliﬁed using Syber Green
Master Mix (Applied Biosystems, Foster City CA). The ampliﬁcation was per-
formed in real-time PCR system HT7900 (Applied Biosystems) using the fol-
lowing conditions: initial denaturation at 95°C for 2 min, followed by 35 cycles
performed at 95°C for 30 s and 60°C for 30 s. The fold-induction/repression in
gene expression by real-time RT-PCR was calculated after adjusting for actin
using the formula 2–ΔΔCt. The primer sequences were reported previously (16,26)
or described in Supplementary Table 1.
Myocardial 4-hydroxynonenal, 3-nitrotyrosine accumulation, DNA
fragmentation, caspase 3, and PARP activities. 4-Hydroxynonenal (4-HNE),
3-nitrotyrosine (3-NT) (markers of oxidative/nitrative stress), DNA fragmenta-
tion, caspase 3, and PARP activities (markers of cell death) in LV tissue extracts/
homogenates were determined using kits from Cell Biolabs (San Diego, CA);
Hycult Biotechnology (Uden, the Netherlands); Roche Diagnostics (Indianapolis,
IN); BioVision (Mountain View, CA); and Trevigen (Gaithersburg,MD), according
to manufacturer’s protocols as described (16,28).
Myocardial AGE accumulation. The AGE protein adducts were determined
from LV tissue homogenates using an OxiSelect AGE enzyme-linked immu-
nosorbent assay (ELISA) kit according to the manufacturer’s instructions (Cell
Biolabs).
Western immunoblot analysis. LV tissues were homogenized in mammalian
tissue protein extraction reagent (TPER; Pierce Biotechnology, Rockford, IL)
supplemented with protease and phosphatase inhibitors (Roche Diagnostics)
and were lysed in radioimmunoprecipitation assay buffer supplemented with
protease and phosphate inhibitors. Then the samples were kept on ice for 1 h,
followed by centrifugation at 13,000 rpm for 30 min at 4°C. The supernatants
were carefully collected, and protein content was determined using a Lowry
assay kit (Bio-Rad, Hercules, CA). A total of 30 mg protein was resolved in 12%
SDS-PAGE and transferred to nitrocellulose membranes (GE Healthcare).
Blocking was done for 2 h at room temperature with 5% nonfat skimmed milk
powder prepared in PBS containing 0.1% Tween 20 (Sigma). After washing
with PBS with Tween 20, membranes were probed with mouse monoclonal
inducible nitric oxide synthase (iNOS) antibody (Cell Signaling Technologies,
Beverly, MA), anti-rabbit p38 MAPK, anti-rabbit phospho-p38 (Thr180/Tyr182)
MAPK, or Jun NH2-terminal kinase (JNK) and phospho JNK (Thr183/Tyr185)
used at a 1:1,000 dilution and incubated overnight at 4°C. The source of the
antibody used for the detection of CB1Rs in the myocardial tissues were
previously described (27). After subsequent washing with PBS with Tween 20,
the secondary antibody, goat anti-rabbit horseradish peroxidase (Pierce Bio-
technology), was used and incubated at room temperature for 1 h. The
membranes then were developed using a chemiluminescence detection kit
(SuperSignal West Pico substrate; Pierce Biotechnology). Blots were quanti-
ﬁed using the Bio-Rad Quantity One program.
Sirius Red staining for collagen. LV myocardial sections were stained with
Picrosirius Red satin solution for 1 h at room temperature. Then slides were
washed in two changes of acidiﬁed water (0.5% acetic acid) for 2 min, and
excess water was removed by blotting. Finally, the sections were dehydrated in
100% alcohol and cleared in xylene and mounted with cover glass (16). The
quantiﬁcation was performed as described at http://rsbweb.nih.gov/ij/docs/
examples/stained-sections/index.html.
Statistical analysis. The results were expressed as mean6 SEM. Differences
among experimental groups were evaluated by ANOVA or Student t test if
appropriate, and the signiﬁcance of differences between groups was assessed
by Tukey post hoc test. The analysis was performed using a statistical soft-
ware package (GraphPad Prism 5; GraphPad Software, Inc., La Jolla, CA).
Signiﬁcance was deﬁned as P , 0.05.
RESULTS
Metabolic variables. Induction of diabetes by multiple
doses of STZ led to reduction in the body weights with in-
crease in the blood glucose levels in WT and CB1
+/+ CB1
2/2
mice, respectively (Supplementary Figs. 1, 2A, and 2B).
However, the blood glucose levels were not different dur-
ing the course of the 12-week study period in CB1
2/2 and
CB1
+/+ mice or in WT mice treated with vehicle or CB1R
antagonists SR141716 (SR1) and AM281 (AM) (Supple-
mentary Figs. 1A and 2A). Similarly, there were no sig-
niﬁcant differences in the HbA1c levels (Supplementary
Figs. 1C and 2C) and the pancreatic insulin content among
corresponding groups (Supplementary Figs. 1D and 2D),
respectively.
Diabetes increases myocardial CB1R expression
and endocannabinoid anandamide levels: improved
diabetes-induced cardiac dysfunction in CB1
2/2 mice.
Diabetic cardiomyopathy was associated with enhanced
LV CB1R expression and anandamide (also known as
N-arachidonoylethanolamide; AEA) levels compared with
nondiabetic animals (control) (Fig. 1A and B; Supplemen-
tary Figs. 3 and 4).
Diabetic cardiomyopathy in CB1
+/+ mice was characterized
by decreased load-dependent (+dP/dt; ejection fraction,
stroke work, cardiac output) and load-independent (Emax,
dP/dtmax–end-diastolic volume relation, preload-recruitable
stroke work) indices of LV systolic contractile function,
and impaired diastolic performance (decreased –dP/dt,
prolonged time constants of LV pressure decay [tWeiss
and tGlantz], increased LV end-diastolic pressure, and de-
creased the slope of the end-diastolic pressure-volume re-
lation [an index of LV stiffness]) (Fig. 1C and D). The
diabetes-induced cardiac dysfunction was less pronounced in
CB1
2/2 mice than in CB1
+/+ mice (Fig. 1C and D). There was
no difference in the cardiac function in control CB1
2/2 and
CB1
+/+ mice. The baseline heart rates were similar in both
CB1
2/2 and CB1
+/+ mice (5206 15, n = 9, vs. 5296 19, n = 9)
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and were decreased to a similar extent after 3 months of
diabetes (467 6 21, n = 9, vs. 452 6 20, n = 9), respectively.
Attenuated diabetes-induced myocardial inﬂammation,
oxidative/nitrative stress, b-MHC isozyme switch,
and AT1R expression in CB1
2/2 mice. LV mRNA ex-
pression of inﬂammatory cytokines, such as tumor necrosis
factor (TNF)-a, interleukin (IL)-1b, adhesion molecules
(intracellular adhesion molecule [ICAM]-1/vascular cell
adhesion molecule [VCAM]-1) (Fig. 2A), iNOS but not en-
dothelial and neuronal nitric oxide synthases (eNOS and
nNOS), cyclooxygenase 2 (COX2) (Fig. 2B; Supplementary
Fig. 5), AT1R, and p47phox (Fig. 2D), was upregulated in the
diabetic myocardium. This result was concordant with the
profound oxidative/nitrative stress, characterized by the ac-
cumulation of lipid peroxidation product 4-hydroxynonenal
and 3-NT (Fig. 2E), enhanced b-MHC isozyme switch
FIG. 1. Enhanced CB1R expression and endocannabinoid (AEA) levels in diabetic hearts; improved diabetes-induced cardiac dysfunction in CB1
2/2
mice. A: After 12 weeks of established diabetes, mice were killed, heart left ventricles were excised, and protein samples were analyzed for
CB1R expression by Western blot analysis. *P < 0.05 vs. control (CO). B: Levels of myocardial anandamide (AEA) were determined by liquid
chromatography–mass spectrophotometry technique as described in RESEARCH DESIGN AND METHODS. *P< 0.05 vs. control. C: Twelve weeks of diabetes
in CB1
+/+ mice was characterized by decreased systolic (attenuated load-dependent [+dP/dt; ejection fraction, stroke work, cardiac output] and
load-independent [D] [Emax, dP/dtmax–end-diastolic volume relation; preload-recruitable stroke work {PRSW}] indices of LV contractile function)
and diastolic (decreased –dP/dt, prolonged time constants of LV pressure decay [tWeiss and tGlantz], increased LV end-diastolic pressure [LVEDP] [C],
and decreased the slope of the end-diastolic pressure-volume relation [EDPVR; an index of LV stiffness {C, D}]) functions. The diabetes-induced
cardiac dysfunction was less pronounced in CB1
2/2 mice than in CB1
+/+ mice (C and D). *P< 0.05 vs. CB1
+/+ control (CO), #P< 0.05 vs. CB1
+/+ diabetes
(Diab); n = 6–9/group. (A high-quality color representation of this ﬁgure is available in the online issue.)
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(decrease in a and increase in b expression [Fig. 2C]), in-
creased iNOS protein expression, and decreased SERCA2a
mRNA expression (Fig. 2F and G). These deleterious effects
induced by diabetes were ameliorated in mice lacking the
CB1R.
Attenuated diabetes-induced myocardial RAGE and
AGE expression/accumulation, MAPK activation, and
cell death in CB1
2/2 mice. Diabetes increased LV RAGE
mRNA expression, AGE accumulation (Fig. 3A), p38/JNK
MAPK induction (Fig. 3B), enhanced caspase 3, PARP
FIG. 2. Attenuation of diabetes-induced myocardial inﬂammation, oxidative/nitrative stress, b-MHC isozyme switch, and AT1R expression in
CB1
2/2 mice. A: LV mRNA expressions of inﬂammatory cytokines and adhesion molecules. B: iNOS and COX2. C: a- and b-MHC. D: AT1R and
p47phox NADPH isoform. E: Oxidative/nitrative stress was determined by measuring 4-HNE and 3-NT in the LV myocardial tissues. F: Protein of
iNOS in the respective groups. G: SERCA2a. *P < 0.05 vs. WT/CB1
+/+ control (CO); #P < 0.05 vs. CB1
+/+ diabetes (Diab); n = 8–9/group. (A high-
quality color representation of this ﬁgure is available in the online issue.)
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activation, and DNA fragmentation in CB1
+/+ diabetic ani-
mals (Fig. 3C and D). These changes were attenuated in
mice lacking the CB1R.
Attenuated diabetes-induced myocardial ﬁbrosis
in CB1
2/2 mice. Diabetes induced marked LV interstitial
ﬁbrosis (Fig. 4A) and enhanced mRNA expressions of ﬁbrotic
markers (connective tissue growth factor, transforming
growth factor-b, ﬁbronectin, and collagen-I) (Fig. 4B) in the
CB1
+/+ mice, which were blunted in diabetic CB1
2/2 mice
(Fig. 4A and B).
CB1R inhibition attenuates diabetes-induced cardiac
dysfunction. Chronic treatment (11 weeks) with CB1R
antagonist SR141716/rimonabant (SR1) improved both
systolic and diastolic cardiac dysfunction associated with
diabetes (Fig. 5A and B). Four weeks of treatment of 8-
week diabetic mice with rimonabant also resulted in similar
FIG. 3. Attenuated diabetes-induced myocardial RAGE and AGE expression/accumulation, MAPK activation, and cell death in CB1
2/2 mice. A: LV
mRNA expression of RAGE and accumulation of AGEs in the myocardium measured by ELISA. B: Representative Western immunoblot for the
analysis of MAPKs (p38 and JNK) in the myocardial tissues. *P < 0.05 vs. CB1
+/+ control (CO); #P < 0.05 vs. CB1
+/+ diabetes (Diab); n = 6/group. C
and D: Markers of cell death (PARP and caspase 3 activities and chromatin fragmentation) in the LV myocardial tissues from the respective groups.
*P < 0.05 vs. WT/CB1
+/+ control (CO); #P < 0.05 vs. CB1
+/+ diabetes (Diab); n = 8/group. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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but less pronounced LV functional improvements (Supple-
mentary Fig. 6).
CB1R inhibition attenuates diabetes-inducedmyocardial
inﬂammation, oxidative/nitrative stress, b-MHC isozyme
switch, AT1R, RAGE and AGE expression/accumulation,
p38/JNK MAPK activation, and cell death. Diabetes
enhanced LV myocardial inﬂammation (Fig. 6A and B),
oxidative/nitrative stress (Fig. 6B, D, and G), mRNA ex-
pression of AT1R, p47phox (Fig. 2D), RAGE, accumulation
of AGE (Fig. 2F), b-MHC isozyme switch (Fig. 2C), and
decreased SERCA2 mRNA, which were attenuated by
chronic treatment (11 weeks) of diabetic animals with CB1R
antagonists SR141716/rimonabant (SR1) and AM281 (AM).
Chronic treatment also attenuated the diabetes-induced LV
FIG. 4. Attenuation of diabetes-induced myocardial ﬁbrosis in CB1
2/2 mice. A: Representative formalin-ﬁxed parafﬁn-embedded myocardial tissue
sections stained with Sirius Red, indicating the marked interstitial ﬁbrosis in the WT diabetic mice, which was attenuated in CB1
2/2 mice. *P <
0.05 vs. CB1
+/+ control (CO); #P < 0.05 vs. CB1
+/+ diabetes (Diab); n = 6/group. B: mRNA expression of ﬁbrosis markers in the myocardial tissues.
*P < 0.05 vs. CB1
+/+ control (CO); #P < 0.05 vs. CB1
+/+ diabetes (Diab); n = 9/group. CTGF, connective tissue growth factor. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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MAPK activation (Fig. 7A) and apoptotic and PARP-
dependent cell death (Fig. 7B and C).
CB1R inhibition attenuates diabetes-inducedmyocardial
ﬁbrosis. Diabetes enhanced myocardial ﬁbrosis charac-
terized by increased collagen accumulation (Fig. 8A) and
enhanced expression of mRNA markers of ﬁbrosis (Fig. 8B),
which were attenuated by chronic treatment (11 weeks) of
diabetic animals with CB1R antagonists SR1 and AM.
DISCUSSION
The salient ﬁndings emanating from the current study
are as follows: 1) diabetes leads to upregulation of CB1R
expression and increase in endocannabinoid ananda-
mide/AEA levels in the myocardium; 2) diabetes-induced
myocardial dysfunction is improved in CB1
2/2 mice or in
diabetic mice treated with CB1 antagonist; 3) genetic deletion
or pharmacological inhibition of CB1Rs attenuates MAPK
activation, cell death, inﬂammation, and oxidative/nitrative
stress in diabetic hearts; 4) likewise, it mitigates expression
of RAGE, AT1R p47(phox) NADPH oxidase subunit, and
impaired expression of SERCA2a and b-MHC isozyme
switch; and 5) the diabetes-induced myocardial accumula-
tion of AGEs and ﬁbrosis are attenuated in CB1
2/2 mice or
in diabetic mice treated with CB1 antagonists.
CB1Rs are expressed in endothelial (29,37,38), vascular
smooth muscle (39,40), and inﬂammatory cells (30,31) and
in cardiomyocytes (26,27,41). It is noteworthy that acti-
vation of cardiovascular CB1Rs by overproduced endo-
cannabinoids has been implicated in the development of
pathophysiological alterations and compromised cardio-
vascular function associated with various forms of shock,
cirrhotic cardiomyopathy, and heart failure (21,26–28).
There is also increasing recognition that in various path-
ological conditions, CB1R activation by endocannabinoids
may trigger activation of signaling pathways (e.g., p38 and
JNK-MAPKs promoting cell death) (21,27,42,43). Recent
studies have also demonstrated that CB1R activation by
endocannabinoids or synthetic agonists in human coro-
nary artery endothelial cells (29) and in primary human
or murine cardiomyocytes (27) triggered increased p38
and JNK activation and ROS generation promoting cell
death. CB1R activation also induced ROS generation and
TNF-a production in human macrophages that depended
on the p38 MAPK pathway and could be attenuated by
its inhibition (30). p38 MAPK inhibition also attenuated
CB1-mediated cell death in endothelial cells and cardio-
myocytes (27,29). Consistently with the above-mentioned
studies in preclinical models of heart failure (26–28),
atherosclerosis (31,44), and diabetic retinopathy (34),
FIG. 5. Attenuation of diabetes-induced cardiac dysfunction by CB1R inhibition. A: Twelve weeks of diabetes in control (CO) mice was charac-
terized by decreased systolic (attenuated load-dependent [+dP/dt; ejection fraction, stroke work, cardiac output] and load-independent [B] [Emax,
dP/dtmax–end-diastolic volume relation; preload-recruitable stroke work {PRSW}] indices of LV contractile function) and diastolic (decreased –dP/
dt, prolonged time constants of LV pressure decay [tWeiss and tGlantz], increased LV end-diastolic pressure (LVEDP) (B), and decreased the slope of
the end-diastolic pressure-volume relation (EDPVR; an index of LV stiffness [B]) functions. Eleven months of treatment with rimonabant (SR141716/
SR1) attenuated the diabetes-induced cardiac dysfunction (A and B). *P < 0.05 vs. vehicle/SR1 control (CO); #P < 0.05 vs. diabetes (Diab); n = 6–9/
group. B: Representative pressure-volume loops after vena cava inferior occlusions demonstrate attenuation of the contractile function and in-
creased diastolic stiffness in diabetic hearts, which is attenuated by CB1R blockade with SR1. Treatment of 8-week diabetic mice for 4 weeks with SR1
attenuated the diabetes-induced functional alterations (Supplementary Fig. 6). *P < 0.05 vs. vehicle control (CO); #P < 0.05 vs. diabetes (Diab);
n = 5–7/group. (A high-quality color representation of this ﬁgure is available in the online issue.)
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CB1 deletion or pharmacological inhibition limits the
vascular or myocardial inﬂammation and/or oxidative/
nitrative stress and interrelated cell death and disease
progression. CB1 antagonists also exerted numerous un-
expected beneﬁcial effects (e.g., anti-inﬂammatory effects)
in clinical trials of obesity beyond their effects on
body weight (23,25,35,45), and peripheral CB1R blockade
appears to be a promising approach in the treatment of
visceral obesity and its cardiometabolic complications
(45,46).
It is noteworthy that increased plasma endocannabinoid
levels positively correlate with coronary circulatory
dysfunction in human obesity (32). We found increased
CB1R expression and endocannabinoid anandamide levels
in the left ventricle of diabetic hearts, which is consistent
with elevated anandamide levels reported in the retina
of patients with diabetic retinopathy (47). Increased endo-
cannabinoid levels have also been reported in serum of
patients with type 2 diabetes and their subcutaneous tissue
(35). Although the mechanism of marked upregulation of
FIG. 6. Attenuation of diabetes-induced myocardial inﬂammation, oxidative/nitrative stress, b-MHC isozyme switch, and AT1R expression by CB1R
antagonists. A: LV mRNA expressions of inﬂammatory cytokines and adhesion molecules. B: iNOS and COX2. C: a- and b-MHC. D: AT1R, p47phox,
gp91phox, and NADPH isoforms. E: SERCA2a. F: mRNA expression of RAGE and accumulation of AGE in the myocardium measured by ELISA. G:
Oxidative/nitrative stress determined by measuring 4-HNE and 3-NT in the LV myocardial tissues in the respective groups as indicated. *P < 0.05
vs. vehicle control (CO); #P < 0.05 vs. diabetes (Diab), n = 8–9/group. AM/SR1 treatments alone in control mice had no signiﬁcant effect on any of
the markers studied (not shown) compared with vehicle-treated controls (CO). (A high-quality color representation of this ﬁgure is available in
the online issue.)
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CB1Rs in various peripheral tissues during multiple disease
conditions associated with increased inﬂammation and/or
oxidative stress has not been evaluated in much detail
(21,45), this process most likely may involve activation of
ROS- and/or inﬂammation-dependent transcription factors.
Indeed, in rat mesangial cells, high glucose upregulates CB1
mRNA expression in an NF-kB–dependent manner. Simi-
larly, hyperglycemia-induced upregulation of CB1 has also
been reported in retina pigment epithelial cells recently
(rev. in 35). CB1 antagonists attenuated the high glucose–
induced apoptosis in mesangial, retina pigment epithelial,
and endothelial cells (35). Reactive oxygen and nitrogen
species and inﬂammatory mediators such as TNF-a, which
are also known to be triggered/upregulated by hypergly-
cemia, have been implicated in enhanced endocannabinoid
production through the activation of NF-kB and other path-
ways in several cell types (including monocytes/macro-
phages and cardiomyocytes), as well as by inactivation and/
or downregulation of the endocannabinoid-metabolizing
enzyme fatty acid amide hydrolase. Consistently, hyper-
glycemia induced fatty acid amide hydrolase– and CB1-
dependent cell death in retina pigment epithelial cells (rev.
in 35). Notably, fatty acid amide hydrolase knockout mice,
which have approximately two- to threefold increased
myocardial anandamide levels, have markedly increased
mortality, cardiac dysfunction, and myocardial cell death
in acute and chronic heart failure models, which are at-
tenuated by CB1 antagonists (28). More importantly, ele-
vated plasma endocannabinoid levels show very strong
positive correlation with coronary circulatory dysfunction
and adverse cardiac events in obese human subjects (32).
Growing evidence implies that oxidative/nitrative
stress together with activation of various proinﬂammatory
and cell death pathways play pivotal roles in the devel-
opment of complex biochemical, mechanical, and struc-
tural alterations associated with diabetic cardiomyopathy
(3–6,10,14–16). Unfortunately, despite the accumulating
knowledge obtained during the past decades, the treat-
ment of diabetic cardiomyopathy is poor and largely symp-
tomatic (1).
In the current study, using a well-characterized mouse
model of type 1 diabetic cardiomyopathy (3,5,14,16), we
evaluated the effects of genetic deletion or pharmacolog-
ical inhibition of CB1Rs with selective CB1 antagonists (for
11 weeks administered after the destruction of pancreatic
b-cells and development of frank type 1 diabetes) on myo-
cardial dysfunction, inﬂammation, oxidative/nitrative stress,
cell death, ﬁbrosis, and interrelated signaling pathways.
FIG. 7. Attenuation of diabetes-induced myocardial MAPK activation and apoptosis by CB1R antagonists. A: Representative immunoblot for the
p38/JNK MAPKs in the myocardial tissues from the respective groups. *P < 0.05 vs. vehicle/AM/SR1 control (CO); #P < 0.05 vs. diabetes (Diab),
n = 6/group. B and C: Cell death markers in the respective groups as indicated. *P < 0.05 vs. vehicle/AM/SR1 control (CO); #P < 0.05 vs. diabetes
(Diab), n = 8/group. (A high-quality color representation of this ﬁgure is available in the online issue.)
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We also evaluated the effect of CB1 inhibition on cardiac
dysfunction associated with already-established diabetic
cardiomyopathy (4 weeks’ treatment of 8-week diabetic
mice).
Consistent with previous reports (3,5–7,13–16), diabetic
cardiomyopathy was characterized by declined diastolic
and systolic myocardial performance, increased oxidative/
nitrative stress (4-HNE, 3-NT, iNOS), activation of various
stress signaling pathways (e.g., JNK and p38 MAPK), en-
hanced expression of RAGE and AT1R, p47(phox) NADPH
oxidase subunit, accumulation of AGEs, inﬂammation (in-
creased expression of TNF-a, IL-1b, COX2, adhesion mol-
ecules ICAM-1 and VCAM-1), b-MHC isozyme switch,
myocardial ﬁbrosis, and decreased expression of SERCA2a.
Compelling evidence (both from rodent models of STZ-
induced type 1 diabetes and human myocardial biopsies)
suggests that the renin-angiotensin system is upregulated
with diabetes and angiotensin II locally through AT1R and
is overexpressed in diabetic hearts or in cardiomyocytes
exposed to high glucose, contributing to the development
of diabetic cardiomyopathy (3,10–13). The beneﬁcial effects
of AT1R blockade in diabetic hearts involve, but are not
limited to, the attenuation of myocardial NADPH oxidase-
dependent (such as p47phox) ROS generation, inﬂam-
mation, cell death, ﬁbrosis, and contractile dysfunction
(3,10–13). Xanthine oxidase, cyclooxygenase, mitochon-
drial electron transport chain, activated inﬂammatory cells,
and uncoupled endothelial nitric oxide synthase may also
FIG. 8. Attenuation of diabetes-induced myocardial ﬁbrosis by CB1R antagonists. A: The representative formalin-ﬁxed parafﬁn-embedded myo-
cardial tissue sections stained with Sirius Red, indicating the marked ﬁbrosis in the diabetic mice, which was attenuated by CB1R antagonists. *P<
0.05 vs. vehicle/AM/SR1 control (CO); #P< 0.05 vs. diabetes (Diab), n = 6/group. B: mRNA expression of ﬁbrosis markers in the myocardial tissues.
*P < 0.05 vs. vehicle/AM/SR1 control (CO); #P < 0.05 vs. diabetes (Diab), n = 9/group. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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represent additional sources of ROS generation in diabetic
hearts (4). Convincing in vitro, ex vivo, and in vivo evidence
suggests that high glucose–induced increased iNOS ex-
pression contributes to cardiac dysfunction associated with
type 1 diabetic cardiomyopathy via formation of reactive
nitrogen species such as peroxynitrite through the rapid
diffusion-limited reaction of superoxide anion (derived from
NADPH oxidase and other sources) and nitric oxide derived
from iNOS (rev. in 4). The above-mentioned reaction is faster
than the decomposition of the superoxide by superoxide
dismutase; therefore, it results in loss of the beneﬁcial effects
of nitric oxide (it is immediately converted to reactive ni-
trogen species in the presence of superoxide before is able to
exert its known protective effects) (4). High glucose–induced
ROS/reactive nitrogen species also induces modiﬁcations
of important proteins involved in Ca2+ handling and myo-
cardial contractility (e.g., SERCA2a) (4) and decrease of their
expression/function (18–20), lipid peroxidation, oxidative
DNA damage, activation of stress signaling, and other cell
death pathways, among others (4). p38 MAPK activation
appears to play an important role in pathogenesis of diabetic
cardiomyopathy, since its pharmacological inhibition atten-
uates not only myocardial dysfunction, but also the ex-
pression of cardiac inﬂammatory markers, such as TNF-a,
IL-1b, IL-6, and myocardial ﬁbrosis (15).
Hyperglycemia and/or hyperglycemia-induced ROS (also
involving enhanced AT1R expression/signaling) may lead
to increased accumulation of products of nonenzymatic
glycation/oxidation of proteins/lipids (AGE) and enhanced
expression of their receptor (RAGE) in the vasculature
and myocardium; these products are thought to play a key
role in the development and progression of cardiovascular
complications of diabetes (7,8). In hearts of type 1 diabetic
rodents, increased expression of RAGE and accumulation
of AGEs have been associated with diabetes-induced
dysfunction and structural alterations (7,8). In diabetic
heart failure patients with reduced LV ejection fraction,
the ﬁbrosis and accumulation of AGEs contribute to the
increased diastolic stiffness, but in patients with normal LV
ejection fraction, the increased cardiomyocyte resting
tension is responsible for this phenomenon (9).
Genetic deletion of CB1R or its pharmacological in-
hibition with selective CB1 antagonists attenuated the di-
abetes-induced myocardial dysfunction, expression of AT1R
and RAGE, accumulation of AGEs, oxidative/nitrative
stress and inﬂammation [4-HNE, 3-NT, iNOS, p47(phox),
TNF-a, IL-1b, COX2, ICAM-1, and VCAM-1], activation of
myocardial p38/JNK MAPKs, cell death, and ﬁbrosis and
also restored the impaired expression of SERCA2a and
MHC isozyme switch.
Interestingly, in recent provocative studies, Hunyady’s
group (rev. in 48) proposed a paracrine transactivation of
the CB1 cannabinoid receptor by AT1 and other Gq/11
protein–coupled receptors, implying that this signaling
may overlap in a pathological situation. Indeed, a recent
study demonstrated that CB1R and AT1R functionally in-
teract forming heteromers, resulting in the potentiation
of AT1R signaling (49). AT1R-CB1R heteromers and en-
hancement of angiotensin II–mediated signaling were
demonstrated in hepatic stellate cells from ethanol-
administered rats (in which CB1R was upregulated), and
CB1 inhibition prevented the angiotensin II–mediated mito-
genic signaling and proﬁbrogenic gene expression (49) un-
derlying the functional signiﬁcance of this interaction. A
recent study also described that chronic CB1R inhibition
led to decreased vascular AT1R expression, NADPH
oxidase–derived vascular oxidative stress, and improved
endothelial function in apolipoprotein E–deﬁcient mice fed
a cholesterol-rich diet (40). In cultured vascular smooth
muscle cells, CB1 antagonists reduced angiotensin II–
mediated NADPH oxidase-dependent ROS generation and
downregulated AT1R expression, whereas CB1R agonist
upregulated AT1R, indicating that AT1R expression is di-
rectly regulated by the CB1R. In light of the above-mentioned
observations, our current study demonstrating decreased
AT1R and p47(phox) expression in hearts of CB1 knockout
diabetic mice or mice treated with CB1 antagonists also
suggests an important interaction of CB1 and AT1R sig-
naling. The downregulation of the AT1R-NADPH oxidase–
ROS pathway by CB1R inhibition/genetic deletion could
also contribute to decreased oxidative stress, AGE/RAGE
accumulation/signaling, MAPK activation, cell death, and
ﬁbrosis observed under these conditions, in addition to the
direct inhibitory effect of the overproduced endocannabi-
noid-CB1 signaling on MAPK activation and its multiple
above-discussed consequences in cardiovascular cell types.
The attenuated myocardial ﬁbrosis and AGE accumulation
in hearts of the diabetic CB1R knockout mice or mice treated
with SR141716/rimonabant is most likely responsible for the
decreased diastolic stiffness observed.
It is noteworthy that our results also suggest that CB1
inhibition may preserve its beneﬁcial effects on contractile
dysfunction even if administered after the development of
established cardiomyopathy. This result coupled with recent
studies demonstrating that CB1R blockade and/or its genetic
deletion attenuates proteinuria and/or vascular inﬂammation
and cell death in experimental models of type 1 diabetic
nephropathy (33), retinopathy (34), and neuropathy (35),
and increases pancreatic b-cell proliferation and mass be-
fore the complete destruction of these cells in early diabetes
(50), are very exciting from a therapeutic point of view.
Collectively, our results strongly suggest that over-
activation of endocannabinoid system and CB1Rs may play
an important role in the pathogenesis of diabetic car-
diomyopathy by facilitating AT1R expression/signaling,
RAGE and AGE expression/accumulation/signaling, MAPK
activation, oxidative/nitrative stress, inﬂammation, cell death,
ﬁbrosis, and contractile dysfunction. Conversely, CB1R
inhibition may be of signiﬁcant beneﬁt in the treatment of
diabetic cardiovascular complications and possibly other
complications.
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